Literature DB >> 17917096

Systemic lupus Erythematosus and IgA multiple myeloma: a rare association?

J Bila1, N Suvajdzic, I Elezovic, M Colovic, D Boskovic.   

Abstract

The coexistence of systemic lupus Erythematosus (SLE) and multiple myeloma (MM) is uncommon and the pathogenetic mechanisms underlying this association remain unclear. We report the case of a woman who was diagnosed with SLE in 1993 aged 57, then developing IgA lambda type MM in the IIB clinical stage 7 years later. The SLE was treated successfully with methylprednisolone and chloroquine, and low dose maintenance steroid was continued with bisphosphonate protection until December 1994 when she suffered multiple vertebral fractures. She continued to receive 4 mg alternate day methylprednisolone and calcitonin until she decided to discontinue her own treatment 2 years later. In 2000, while still in stable SLE remission, she was diagnosed with MM. Protein electrophoresis revealed the IgA lambda paraprotein (40.5 g/l) and she had a Bence Jones (BJ) proteinuria of the lambda light chain type. Bone marrow trephine biopsy revealed a massive patchy infiltrate of abnormal plasmocytes (70%), while an extensive x-ray skeletal survey did not show any new fractures or osteolysis. The patient was treated according to the VMCP protocol without attaining a plateau phase. There was a similar poor clinical response to second and third line treatments (VAD, Thalidomide, Melphalan, and high dose dexamethasone). After 4 years of refractory disease the patient died from severe bilateral pneumonia. This case is discussed with reference to the literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917096     DOI: 10.1007/s12032-007-0047-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.738


  38 in total

1.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

Authors:  H Avet-Loiseau; J Y Li; T Facon; C Brigaudeau; N Morineau; F Maloisel; M J Rapp; P Talmant; F Trimoreau; A Jaccard; J L Harousseau; R Bataille
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

Review 2.  Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis.

Authors:  E F Remmers; H Sano; R L Wilder
Journal:  Semin Arthritis Rheum       Date:  1991-12       Impact factor: 5.532

3.  Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Authors:  M Chesi; L A Brents; S A Ely; C Bais; D F Robbiani; E A Mesri; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

Review 4.  Systemic lupus erythematosus and multiple myeloma: a rare association.

Authors:  A Afeltra; A Amoroso; P Garzia; M A Addessi; A Pulsoni; L Bonomo
Journal:  Semin Arthritis Rheum       Date:  1997-06       Impact factor: 5.532

Review 5.  Oncogene expression and regulation in normal lymphocytes and lymphocytes from patients with autoimmune diseases.

Authors:  D T Boumpas; E G Eleftheriades; S Barez; G C Tsokos
Journal:  Anticancer Res       Date:  1988 Sep-Oct       Impact factor: 2.480

6.  Haematopoietic cancer and medical history: a multicentre case control study.

Authors:  P Vineis; P Crosignani; C Sacerdote; A Fontana; G Masala; L Miligi; O Nanni; V Ramazzotti; S Rodella; E Stagnaro; R Tumino; C Viganò; C Vindigni; A S Costantini
Journal:  J Epidemiol Community Health       Date:  2000-06       Impact factor: 3.710

7.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.

Authors:  R Richelda; D Ronchetti; L Baldini; L Cro; L Viggiano; R Marzella; M Rocchi; T Otsuki; L Lombardi; A T Maiolo; A Neri
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

8.  Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus.

Authors:  L Mellemkjaer; V Andersen; M S Linet; G Gridley; R Hoover; J H Olsen
Journal:  Arthritis Rheum       Date:  1997-04

9.  Systemic lupus erythematosus with paraproteinemia.

Authors:  L Rubin; M B Urowitz; W Pruzanski
Journal:  Arthritis Rheum       Date:  1984-06

10.  Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.

Authors:  Jonathan B Pollett; Suzanne Trudel; Daniel Stern; Zhixiong H Li; A Keith Stewart
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

View more
  4 in total

1.  Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.

Authors:  Haipeng Shao; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Nelson Spector; Cristiane Milito; Jose Carlos Morais; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

2.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.

Authors:  Shir Azrielant; Shmuel Tiosano; Abdulla Watad; Naim Mahroum; Aaron Whitby; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 3.  Early onset multiple myeloma in a patient with systemic lupus erythematosus: a case report and literature review.

Authors:  Jin Woo Choi; Seung Woo Han; Ki Tae Kwon; Gun Woo Kim
Journal:  Clin Rheumatol       Date:  2010-03-07       Impact factor: 2.980

4.  Non-lymphoma hematological malignancies in systemic lupus erythematosus.

Authors:  Mary Lu; Sasha Bernatsky; Rosalind Ramsey-Goldman; Michelle Petri; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen M Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Soren Jacobsen; Mary Anne Dooley; Christine A Peschken; Graciela S Alarcón; Ola Nived; Lena Gottesman; Lindsey A Criswell; Gunnar Sturfelt; Lene Dreyer; Jennifer L Lee; Ann E Clarke
Journal:  Oncology       Date:  2013-10-02       Impact factor: 2.935

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.